Format

Send to

Choose Destination
Curr Opin HIV AIDS. 2010 Sep;5(5):397-403. doi: 10.1097/COH.0b013e32833d2e39.

Update on mucosal HIV vaccine vectors.

Author information

1
HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. aduerr@hvtn.org

Abstract

PURPOSE OF REVIEW:

HIV's primary site of infection is at mucosal surfaces. To successfully defend against sexually transmitted diseases (STDs), including HIV, protection may need to be specifically elicited at the mucosal interface, where the organism enters the host. Recent advances in measuring adaptive responses at mucosal sites and optimization of techniques for low-dose repeated mucosal challenge in nonhuman primate animal models allow more in depth studies of mucosal vaccine vectors.

RECENT FINDINGS:

Although parenterally administered vaccines can elicit responses at mucosal sites, vaccination of mucosal sites is being explored in an attempt to increase the frequency, strength and distribution of the adaptive mucosal response. Recent studies in nonhuman primates involve vaccination of the gastrointestinal tract and rectum, as well as the nose, oropharynx or respiratory tree in an attempt to elicit responses at the distal mucosal sites where HIV transmission occurs, the rectum and genital tract.

SUMMARY:

Recent experiments in nonhuman primates indicate that vaccination at mucosal sites can elicit robust responses in the periphery and at mucosal sites, although the response pattern varies widely by route and regimen used. For most regimens, disease course after challenge did not differ by route of vaccination.

PMID:
20978380
DOI:
10.1097/COH.0b013e32833d2e39
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for Fred Hutchinson Cancer Research Ctr Arnold Library
Loading ...
Support Center